AMWA-EMWA-ISMPP joint position statement on medical publications, preprints, and peer review. Curr. Med. Res. Opin. 37:861–866, 2021.
2.
CasassusB.European law could boost clinical trials reporting. Science. 373:268–268, 2021.
3.
DunnB., SteinP., TempleR., and CavazzoniP. An appropriate use of accelerated approval—Aducanumab for Alzheimer's disease. N. Engl. J. Med. 2021 (In press).
4.
DunnB., SteinP., and CavazzoniP. Approval of aducanumab for Alzheimer disease—the FDA's perspective. JAMA Intern. Med. 2021 (In press).
5.
SteinbrookR. The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. JAMA Intern. Med. 2021 (In press).
6.
AllenR.C., BradleyE.A., FanteR.G., and LucarelliM.J.A perspective on the current role of teprotumumab in treatment of thyroid eye disease. Ophthalmology. 128:1125–1128, 2021.
